BACKGROUND: The aim of this open, pilot supplement registry study was to evaluate the protective, preventive effects of Robuvit (R) on professional-related fatigue symptoms and on aspects of cognitive functions, professional attitudes and decision-making in healthy nurses under professional stress and with increased oxidative stress.METHODS: In total, 40 subjects, aged 30-37, completed the 4-week registry study. A control group of 20 subjects used only the standard management (SM) and one group of 20 subjects took 300 mg Robuvit (R) in addition. Safety and tolerability of Robuvit (R) were optimal. The two registry groups were comparable at inclusion.RESULTS: The overall scores of the real daily life and tasks questionnaire after 4 weeks were significantly higher in the Robuvit (R) group (P<0.05) as compared to controls. It increased from 4.3 +/- 0.4 at baseline to 6.78 +/- 0.8 after 4 weeks of Robuvit (R) intake and from 4.2 +/- 0.5 to 5.12 +/- 1.0 in the control group. The supplementation significantly improved the subjective perception of fatigue in comparison with controls (P<0.05). A practical professional score evaluation provided an indication of professional attitude and stamina, in difficult, stressful working conditions under continuous pressure. The results showed that after 4-week supplementation, all assessed parameters improved significantly and the difference with controls was statistically significant (P<0.05). Furthermore, oxidative stress as plasma free radicals decreased significantly in the Robuvit (R) group (P<0.05) but not in the control group.CONCLUSIONS: Robuvit (R) supplementation appears to improve most symptoms related to work-induced fatigue, stress and cognitive function and supports stamina. Further evaluations need to be planned according to the concept of this pilot registry in a field that requires more attention.
Prevention of work-related stress, fatigue, loss of cognitive function, improved attention and recovery of stamina with Robuvit® in professionals with increased oxidative stress
Saggino, Aristide;Cotellese, Roberto;Feragalli, Beatrice
2021-01-01
Abstract
BACKGROUND: The aim of this open, pilot supplement registry study was to evaluate the protective, preventive effects of Robuvit (R) on professional-related fatigue symptoms and on aspects of cognitive functions, professional attitudes and decision-making in healthy nurses under professional stress and with increased oxidative stress.METHODS: In total, 40 subjects, aged 30-37, completed the 4-week registry study. A control group of 20 subjects used only the standard management (SM) and one group of 20 subjects took 300 mg Robuvit (R) in addition. Safety and tolerability of Robuvit (R) were optimal. The two registry groups were comparable at inclusion.RESULTS: The overall scores of the real daily life and tasks questionnaire after 4 weeks were significantly higher in the Robuvit (R) group (P<0.05) as compared to controls. It increased from 4.3 +/- 0.4 at baseline to 6.78 +/- 0.8 after 4 weeks of Robuvit (R) intake and from 4.2 +/- 0.5 to 5.12 +/- 1.0 in the control group. The supplementation significantly improved the subjective perception of fatigue in comparison with controls (P<0.05). A practical professional score evaluation provided an indication of professional attitude and stamina, in difficult, stressful working conditions under continuous pressure. The results showed that after 4-week supplementation, all assessed parameters improved significantly and the difference with controls was statistically significant (P<0.05). Furthermore, oxidative stress as plasma free radicals decreased significantly in the Robuvit (R) group (P<0.05) but not in the control group.CONCLUSIONS: Robuvit (R) supplementation appears to improve most symptoms related to work-induced fatigue, stress and cognitive function and supports stamina. Further evaluations need to be planned according to the concept of this pilot registry in a field that requires more attention.File | Dimensione | Formato | |
---|---|---|---|
BELCARO ET AL., 2021.pdf
Solo gestori archivio
Tipologia:
Documento in Post-print
Dimensione
677.24 kB
Formato
Adobe PDF
|
677.24 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.